Emilio Ragosa

Securities Offerings

• IPOs for several biotech companies, as well as many underwritten follow-on public offerings
• Several biotech companies with their recent private investment in public equity (PIPE) deals, registered direct offerings (RDOs), at-the-market (ATM) and equity-line offerings
• Several multinational pharma companies in connection with their strategic investments in US public companies
• A medical device company in a reverse merger, now commonly referred to as an alternative public offering
• Several funds in PIPEs and RDOs
• Underwriters in a specialty pharma IPO

Mergers and Acquisitions

• A private biotech company in its sale to a large pharma company for up to US$7 billion
• Combination of a public biotech company client with private biotech and subsequent up-listing on stock exchange
• An Italian specialty pharma company with its acquisition of a US public specialty pharma company
• A public biotech company in its sale to strategic buyer
• A public company in its sale to private equity firm
• A public clinical research organization in several private acquisitions of e-clinical companies
• A public clinical research organization in a public tender offer of a public EDC company
• Multiple private tech and biotech companies in their critical sale transactions

Private Placements

• Private tech and biotech companies with their successful angel and venture financings
• Venture capital firms and other funds with their investments in tech and biotech companies
• Pension funds with investments in private companies

Chambers USA

• Band 2, New Jersey Corporate/M&A, (2026)
• Band 3, New Jersey Corporate/M&A, (2019 – 2025)

The Legal 500 United States

• Recommended, Life Sciences, (2026)
• Recommended, Capital Markets: Equity Offerings, (2025 – 2026)
• Recommended, M&A Middle-Market ($500M-999M), (2019)
• Recommended, Venture Capital & Emerging Companies, (2018 – 2019)

Additional Recognitions

• Selected as Winning Deal Team – Cross-border Turnaround Deal of the Year, Global M&A Network, (2021) 
• Life Sciences Star: Finance and Transactional, LMG Life Sciences Guide, (2016 – 2017)
• 40 Under 40, New Jersey Law Journal, (2010)

^{For more information, pursuant to New Jersey Lawyer Advertising guidance, please click here.}

• "Venture Capital's New Era: Dynamic Shifts and Future Trends," BioNJ Bio Partnering Conference, May 14, 2024
•  "Chasing Breakthrough Innovation in a Time of Uncertainty," BioNJ C-Suite Summit, October 6, 2023
• "Transitioning to the 'Next Normal': Biopharma's Role in Addressing the COVID-19 Crisis and What's Next," BioNJ Virtual C-Suite Summit, October 14, 2021
• "NACD Princeton Chapter Presentation – An Activist Director: Good or Bad for Your Board?," April 21, 2016
• "The Generational Disruption of Corporate America," NACD New Jersey Chapter, October 21, 2015